FOR IMMEDIATE RELEASE
June 29, 2026
CONTACT:
Kyra Smith (Crapo)
Washington, D.C.—U.S. Senator Mike Crapo (R-Idaho) joined Senator Bill Cassidy, M.D. (R-Louisiana), U.S. Representative Chris Smith (R-New Jersey) and 90 additional Republican lawmakers in filing an amicus brief supporting Louisiana’s lawsuit to protect women and their unborn children from dangerous chemical abortion drugs.
“The FDA has the responsibility to ensure every drug meets rigorous safety standards, especially when vulnerable lives are at stake,” said Crapo. “We must restore commonsense safeguards for chemical abortion drugs and ensure the law is faithfully followed to protect women and their unborn babies.”
“In-person dispensing requirements for chemical abortion drugs saves babies and protects women from coercion,” said Dr. Cassidy. “As a strong pro-life doctor, I will always defend the health and safety of mothers and unborn life. These commonsense safeguards must be reinstated immediately.”
“The fight to protect women and unborn children from the dangers of mail-order baby poison pills continues,” said Representative Smith. “The Biden Administration’s reckless removal of the in-person dispensing requirements for mifepristone has been a blight upon the FDA for over three years now. We must reverse this pernicious policy, which continues to take and harm the lives of countless mothers and unborn babies.”
Background:
In October 2025, Louisiana Attorney General Murrill filed a lawsuit on behalf of the State of Louisiana and Rosalie Markezich, a victim of the harmful decision to remove the in-person dispensing requirement for dangerous chemical abortion drugs. Because of the previous Administration’s policy, Rosalie’s boyfriend was able to order chemical abortion pills online from an abortionist in California and coerced her to take the drug to kill her unborn child.
The Republican lawmakers argue that the Biden Administration violated federal law by removing the in-person dispensing requirement, and these protections should be reinstated. Additionally, the amicus brief supports Attorney General Murrill’s motion for preliminary relief, asking for a preliminary injunction ordering the Food and Drug Administration to suspend or withdraw the 2023 Risk Evaluation and Mitigation Strategy while the case proceeds.
Read the full amicus brief here.
About Mike Crapo
Senator Mike Crapo has represented Idaho in the Senate since 1999, following three terms in the U.S. House and eight years in the Idaho State Senate. A lifelong Idahoan, he currently serves as Chairman of the Senate Finance Committee.
